Korro Bio, Inc. (KRRO)
NASDAQ: KRRO · Real-Time Price · USD
9.64
-0.07 (-0.72%)
Oct 2, 2026, 4:00 PM EDT - Market closed
Korro Bio Revenue
Korro Bio had revenue of $2.38M in the twelve months ending June 30, 2026, down -62.08% year-over-year. In the year 2025, Korro Bio had annual revenue of $6.39M with 181.46% growth.
Revenue (ttm)
$2.38M
Revenue Growth
-62.08%
P/S Ratio
59.59
Revenue / Employee
$41,789
Employees
57
Market Cap
141.96M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.39M | 4.12M | 181.46% |
| Dec 31, 2024 | 2.27M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Codexis | 77.68M |
| Atrium Therapeutics | 35.84M |
| Innate Pharma | 11.21M |
| Humacyte | 2.12M |
| Molecular Partners AG | 856.30K |
| Outlook Therapeutics | -1.16M |
KRRO News
- 22 days ago - Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Korro to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 1 month ago - Korro Bio reports Q2 EPS ($1.07), consensus ($1.28) - TheFly
- 1 month ago - Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 month ago - Korro Bio Quarterly report: Q2 2026 - Filings
- 1 month ago - Korro Bio Earnings release: Q2 2026 - Filings
- 2 months ago - Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Korro Bio initiated with an Outperform at LifeSci Capital - TheFly